Patents Represented by Attorney, Agent or Law Firm Janet E. Hasak
  • Method of stimulating immune response
    Patent number: 5202119
    Abstract: A method is disclosed for stimulating a mammal's or avian's immune response, particularly immune-compromised mammals, by administration of IGF-I, alone or in combination with growth hormone. Preferably, the IGF-I is native-sequence, mature human IGF-I.
    Type: Grant
    Filed: June 28, 1991
    Date of Patent: April 13, 1993
    Assignee: Genentech, Inc.
    Inventors: Ross G. Clark, Paula M. Jardieu
  • Assay for free IGF-I, IGF-II, and GH levels in body fluids
    Patent number: 5198340
    Abstract: A method and kit are provided for determining levels in a biological sample of free IGF-I, IGF-II, or GH ligand that is normally associated in the sample with a binding protein. This method involves contacting the body fluid with an immobilized unlabeled capture reagent and incubating at 4.degree.-10.degree. C. for no greater than about 4 hours to bind the free ligand contained in the body fluid; separating the fluid from the immobilized capture reagent; and measuring the level of free ligand now bound to the capture reagent. This method is particularly useful to determine levels of free IGF-I in serum or plasma.
    Type: Grant
    Filed: January 17, 1991
    Date of Patent: March 30, 1993
    Assignee: Genentech, Inc.
    Inventor: Venkat R. Mukku
  • Reconstitutable lyophilized protein formulation
    Patent number: 5192743
    Abstract: A formulation for proteins is provided that comprises a lyophilized mixture of a protein, a water-soluble etherified cellulose in an amount that upon reconstitution of the formulation will be sufficient to form a gel, and an excipient to facilitate rehydration of the gel and to maintain protein integrity during storage of the lyophilized gel product. When reconstituted to a gel, this formulation can be applied, for example, to tissue in need of treatment.
    Type: Grant
    Filed: January 16, 1992
    Date of Patent: March 9, 1993
    Assignee: Genentech, Inc.
    Inventors: Chung C. Hsu, Hoc M. Nguyen, Sylvia S. Wu
  • Use of binding protein with IGF-I as an anabolic growth promoting agent
    Patent number: 5187151
    Abstract: A method is disclosed for producing an anabolic state in a mammal by co-administration by subcutaneous injection of a combination of effective amounts of IGF-I and an IGF binding protein in a defined molar ratio in the absence of growth hormone so as to produce a greater anabolic response in the mammal than that achieved using IGF-I alone in an amount equal to that used for IGF-I in the combination. Preferably, the IGF-I is native-sequence, mature human IGF-I, the binding protein is IGFBP-3, and the mammal is human or a non-human animal of economic importance such as a cow or pig.
    Type: Grant
    Filed: February 12, 1991
    Date of Patent: February 16, 1993
    Assignee: Genentech, Inc.
    Inventors: Ross G. Clark, Venkat R. Mukku
  • Nucleic acid encoding TGF-.beta. its uses
    Patent number: 5168051
    Abstract: Nucleic acid encoding TGF-.beta. has been isolated and cloned into vectors which are replicated in bacteria and expressed in eukaryotic cells. TGF-.beta. is recovered from transformed cultures for use in known therapeutic modalities. Nucleic acid encoding TGF-.beta. is useful in diagnosis and identification of TGF-.beta. clones.
    Type: Grant
    Filed: August 4, 1989
    Date of Patent: December 1, 1992
    Assignee: Genentech, Inc.
    Inventors: Rik M. A. Derynck, David V. Goeddel
  • Mammalian expression of the bone morphogenetic protein-2B using BMP2A/BMP2B fusion
    Patent number: 5168050
    Abstract: A DNA construct is provided comprising DNA encoding a mature BMP-2 upstream of which is DNA encoding a precursor portion of a mammalian protein other than the BMP-2. Also provided are mammalian expression vectors and hosts containing such a DNA construct and methods for improved expression using such construct.
    Type: Grant
    Filed: May 24, 1990
    Date of Patent: December 1, 1992
    Assignee: Genentech, Inc.
    Inventors: R. Glenn Hammonds, Jr., Anthony J. Mason
  • Method for increasing fertility in males
    Patent number: 5166190
    Abstract: A method is provided for increasing fertility in a male mammal exhibiting germinal epithelium failure comprising administering to the mammal an effective amount of activin. Preferably, the administration is to the testis of the mammal.
    Type: Grant
    Filed: January 8, 1990
    Date of Patent: November 24, 1992
    Assignee: Genentech, Inc.
    Inventors: Jennie P. Mather, Kenneth M. Attie
  • Method of inducing bone growth using TGF-.beta.
    Patent number: 5158934
    Abstract: A method is provided for generation of bone at a site of an animal where skeletal tissue is deficient comprising administering to the animal, locally at the bone site in the presence of a source of osteogenic cells, an effective amount of a composition comprising TGF-.beta. in a pharmaceutically acceptable carrier, provided that such composition excludes a bone morphogenetic cofactor, the composition being administered in an amount effective to induce bone growth at the bone site. Also provided is a device for implantation into a site of an animal where skeletal tissue is deficient comprising a device treated with an effective amount of a composition comprising TGF-.beta. and a source of osteogenic cells in a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: September 1, 1989
    Date of Patent: October 27, 1992
    Assignee: Genentech, Inc.
    Inventors: Arthur J. Ammann, Christopher G Rudman
  • Method for the treatment of grafts prior to transplantation using TGF-.beta .
    Patent number: 5135915
    Abstract: A method is provided for the treatment of grafts such as tissue or organs prior to transplantation into a suitable host. The grafts are incubated, coated, or perfused with TGF-.beta. for an effective time for the uptake of the agent into the grafts and induction of its biological effects. The thus-treated graft is then transplanted into a compatible host, preferably a human host.
    Type: Grant
    Filed: October 14, 1988
    Date of Patent: August 4, 1992
    Assignee: Genentech, Inc.
    Inventors: Christine W. Czarniecki, Michael A. Palladino, Eli Shefter
  • Method of restoring normal growth, weight gain or lean body mass in patients with glucocorticoid excess by administering IGF-I
    Patent number: 5128320
    Abstract: A method is disclosed for at least partially restoring normal growth, weight gain, and lean body mass of a mammal afflicted with glucocorticoid excess. This method comprises the administration to the mammal of an effective amount of IGF-I. Preferably, the mammal is a child and the IGF-I is native-sequence or brain IGF-I.
    Type: Grant
    Filed: January 18, 1990
    Date of Patent: July 7, 1992
    Assignee: Genentech, Inc.
    Inventors: Theodore J. Hahn, Christopher G. Rudman
  • Method of enhancing growth in patients using combination therapy
    Patent number: 5126324
    Abstract: A method is disclosed for enhancing growth of a mammal by administration of a combination of effective amounts of IGF-I and GH so as to enhance the growth of the mammal over the enhancement in growth achieved using either IGF-I or GH alone in an amount equal to that used for either IGF-I or GH, respectively, in the combination. Preferably, the mammal is a child, the IGF-I is native-sequence, mature human IGF-I or human brain IGF-I, and the GH is native-sequence, mature human GH with or without a terminal methionine. In another preferred embodiment, the mammal is a non-human animal of economic importance such as a cow or pig.
    Type: Grant
    Filed: June 7, 1990
    Date of Patent: June 30, 1992
    Assignee: Genentech, Inc.
    Inventors: Ross G. Clark, Michael J. Cronin
  • Biologically active polypeptides based on transforming growth factor-.beta.
    Patent number: 5118791
    Abstract: A polypeptide is provided that excludes (a) a full-length mature TGF-.beta. molecule or precursor TGF-.beta. molecule or deletion variants of mature or precursor TGF-.beta.molecules in which from about 1 to 10 amino acid residues have been delected, (b) a polypeptide of the sequence: Cys-Val-Arg-Gln-Leu-Tyr-Ile-Asp-Phe-Arg-Lys-Asp-Leu-Gly-Trp-Lys, and (c) a polypeptide of the sequence: Arg-Asn -Leu-Glu-Glu-Asn-Cys-Cys-Val-Arg-Pro-Leu-Tyr-Ile-Asp-Phe-Arg-Gln-Asp-Leu, said polypeptide comprising an amino acid sequence that is based on conserved sequences in the family of TGF-.beta. molecules. Such polypeptides are particularly useful therapeutically as immunosuppressive agents when coupled to carrier proteins or crosslinked to form polymers.
    Type: Grant
    Filed: June 13, 1991
    Date of Patent: June 2, 1992
    Assignee: Genentech, Inc.
    Inventors: John P. Burnier, George J. Cianciolo
  • Tissue plasminogen activator having zymogenic or fibrin specific properties
    Patent number: 5108901
    Abstract: Tissue plasminogen activator (t-PA) zymogens and variants are prepared, including a fibrinolytically active variant of t-PA that has an amino acid alteration at a site within the protease domain of t-PA as compared with the corresponding wild-type t-PA, which alteration renders the variant zymogenic in the presence of plasmin-degraded fibrinogen, and/or fibrin (or plasma clot) specific, as compared to the corresponding wild-type t-PA. DNA sequences can be prepared that encode the zymogens and variants, as well as expression vectors incorporating the DNA sequences, and host cells transformed with the expression vectors. The zymogens and variants may be used in a pharmaceutical preparation to treat a vascular disease or condition or to prevent fibrin deposition or adhesion formation or reformation in mammals.
    Type: Grant
    Filed: July 24, 1989
    Date of Patent: April 28, 1992
    Assignee: Genentech, Inc.
    Inventors: Stephen Anderson, William F. Bennett, David Botstein, Deborah L. Higgins, Nicholas F. Paoni, Mark J. Zoller
  • DNA sequences encoding yeast ubiquitin hydrolase
    Patent number: 5108919
    Abstract: A ubiquitin hydrolase is provided having a purity of at least 70% homogeneity based on the weight of the total protein in the composition. Also provided are DNA sequences encoding ubiquitin hydrolases, as well as expression systems for their recombinant production. Processes are provided for purification of a ubiquitin hydrolase from eukaryotes and for its use in recovering any desired polypeptide free from its fusion at its N-terminus with ubiquitin.
    Type: Grant
    Filed: December 14, 1988
    Date of Patent: April 28, 1992
    Assignee: Genentech, Inc.
    Inventors: Chung-Cheng Liu, Harvey I. Miller
  • Method for inhibiting follicular maturation
    Patent number: 5102868
    Abstract: A method is provided for inhibiting the maturation of follicles in the ovary of a femal mammal comprising administering to the ovary of the mammal an effective amount of activin. This method is particularly effective in treating polycystic ovarian disease.
    Type: Grant
    Filed: January 8, 1990
    Date of Patent: April 7, 1992
    Assignee: Genentech, Inc.
    Inventors: Teresa K. Woodruff, Jennie P. Mather
  • Combination therapy using interleukin-2 and tumor necrosis factor
    Patent number: 5098702
    Abstract: Anti-tumor activity in mammals can be augmented by administering to the mammalian host a synergistically effective amount of TNF and IL-2 or of TNF and IFN-.beta., or of TNF, IL-2 and IFN-.beta. in combination. The composition of TNF and IL-2 and/or IFN-.beta. may be prepared in vitro or administered separately to the host. If the TNF and IL-2 are administered sequentially, the TNF must be administered prior to the IL-2 to obtain synergy. The composition is useful for treating such cancers as mastocytoma, melanoma, leukemia, lymphoma, mammary adenocarcinoma, and pharyngeal squamous cell carcinoma.
    Type: Grant
    Filed: June 26, 1989
    Date of Patent: March 24, 1992
    Assignee: Cetus Corporation
    Inventors: Robert Zimmerman, Jeffrey L. Winkelhake
  • Nucleic acid encoding .beta. chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid
    Patent number: 5089396
    Abstract: DNA encoding the prepro inhibin .alpha. and .beta. chains has been isolated. This DNA is ligated into expression vectors and used to transform host cells for the preparation of inhibin or activin. Also provided are prohormone domains and other inhibin .alpha. and .beta. chain derivatives having therapeutic or diagnostic interest. The compositions provided herein are useful in the manipulation of fertility in animals.
    Type: Grant
    Filed: July 5, 1988
    Date of Patent: February 18, 1992
    Assignee: Genentech, Inc.
    Inventors: Anthony J. Mason, Peter H. Seeburg
  • DNA encoding human plasminogen modified at the cleavage site
    Patent number: 5087572
    Abstract: A cleavage-resistant plasminogen molecule is provided that is conveniently produced in recombinant cells by expression of a nucleic acid sequence encoding the plasminogen molecule. Preferably the plasminogen is a sequence variant with a modification in its two-chain cleavage site. The plasminogen molecule may be purified, acylated, complexed with acylated or non-acylated fibrinolytic enzymes, and formulated into pharmaceutical compositions for use in thrombolytic therapy.
    Type: Grant
    Filed: December 1, 1989
    Date of Patent: February 11, 1992
    Assignee: Genentech, Inc.
    Inventors: Francis J. Castellino, Deborah L. Higgins
  • Oligonucleotides and kits for detection of HTLVI and HTLVII viruses by hybridization
    Patent number: 5079351
    Abstract: The presence or absence of a nucleic acid sequence of an isolate of HTLVI and/or HTLVII in a sample containing one or more nucleic acids and suspected of containing such sequence can be detected by amplifying the sequence using primers to form extension products as templates and detecting the amplified product if it is present. This may be accomplished by adding a labeled hydridization probe to the amplified product, either free in solution or after immobilization on a solid support.
    Type: Grant
    Filed: November 26, 1986
    Date of Patent: January 7, 1992
    Assignee: Cetus Corporation
    Inventors: John J. Sninsky, Shirley Y. Kwok, Bernard Poiesz
  • Purified activin B composition
    Patent number: 5071834
    Abstract: A pharmaceutical composition and method are provided for erythropoietin therapy, such as treatment of an anemic disease, wherein an effective amount of activin with two beta.sub.B chains formulated in a pharmaceutically acceptable carrier is administered to a patient or animal in need of such therapy. Preferably the activin is human and the composition is administered parenterally.
    Type: Grant
    Filed: October 12, 1990
    Date of Patent: December 10, 1991
    Assignee: Genentech, Inc.
    Inventors: Louis E. Burton, Anthony J. Mason, Charles H. Schmelzer